Clinical Trials Supply Chains Reimagined.

Clinical Trials Supply Chains Reimagined.

Anne Stolle, Global Key Account Clinical Trials

Release date

Clinical Trials Supply Chains Reimagined.

With the first half of the year of events and conferences in Clinical Trials over, Berlinger has been actively participating in several key industry gatherings across Europe and the US. Dr. Anne Stolle, having attended these events, now provides a summary of her key insights.

Over the past few weeks and months, I have attended several industry meetings and gained valuable insights that can significantly benefit our customers.
Therefore, let me share with you my observations:

Common Trends that I kept seeing were the following:

  • Increasing Diversity in Clinical Trials: Ensuring diverse participant demographics in clinical trials is crucial for achieving comprehensive and reliable outcomes. This emphasis on diversity was a recurring theme, highlighting the need for inclusivity in research.
  • Applying Patient-Centricity in Clinical Trial Setup: There is a strong focus on prioritizing patient needs and experiences in clinical trials. This approach is seen as vital for improving participation rates and data quality.
  • Complexity of the Supply Chain for Advanced Medicinal Products: The supply chain for advanced medicinal products, such as cell and gene therapies, is becoming increasingly complex. Ensuring precise and reliable logistics for these products is a significant concern in the industry.
  • Increasing Efficiency and Reducing Waste: A continuous need exists to enhance operational efficiency and minimize waste to reduce costs. This trend drives the demand for predictive technology and integrated systems to avoid data silos.

New or Intensified Trends that came up more recently were the following:

  • Net Zero Carbon Emissions: Sustainability is now a key focus, with a growing emphasis on reducing carbon footprints. Net zero carbon emissions are on the agenda not only in the pharmaceutical and life sciences sectors but also in clinical trials.
  • Artificial Intelligence (AI): AI is a hot topic, with discussions centered around its potential value. However, the industry is still evaluating where AI can add the most value, particularly in clinical trials and supply chain management.
  • Handling Disruptions and Unexpected Events: Disruptions and unexpected events remain a significant issue within the clinical supply chain, even post-COVID-19. This has led to a heightened need for predictive technology, increased precision, technical innovations, real-time technology, data-driven decision-making, and advanced analytics. The potential role of AI in addressing these challenges is being explored but remains uncertain.

These insights reflect the evolving priorities and challenges within the industry, offering valuable perspectives for enhancing our strategies and solutions.

As we look ahead, we are excited to continue these important discussions and explore new opportunities at our upcoming fall events across Europe and the US. Meet Anne at the GCSG 2024 European Knowledge Forum in Malta from October 15 to 17.

Connect with the Berlinger team at the events to delve deeper into these trends and work together to develop innovative solutions for the future of clinical trials. Stay tuned for more details, we look forward to hearing from you!